Develops vaccines for infectious diseases.
Jun 2026Revenue $414M/yrExpenses $648M/yr
No trendCash runway over 10 years from Jun 2026
Figures by year
When will Novavax be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $414M and expenses $648M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.12B | $671M | $453M |
| Dec 2024 | $682M | $931M | −$249M |
| Dec 2023 | $984M | $1.55B | −$567M |
| Dec 2022 | $1.98B | $2.63B | −$645M |
| Dec 2021 | $1.15B | $2.83B | −$1.69B |
| Dec 2020 | $476M | $892M | −$417M |
| Dec 2019 | $18.7M | $139M | −$121M |
| Dec 2018 | $34.3M | $208M | −$174M |
| Dec 2017 | $31.2M | $203M | −$172M |
| Dec 2016 | $15.4M | $284M | −$269M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.